In a competitive market, M&A can be a valuable tool for ensuring that your company has the right products and capabilities needed to deliver on market expectations. However, most mergers never achieve the strategic and financial objectives that originally justified the investment. Success requires robust processes, planning, and analytics – before and after the deal.
We believe the critical starting point for M&A strategy is a clear understanding of the external market and a company’s capabilities and objectives. Numerof’s disciplined, structured approach takes macro trends and context into account, helping pharmaceutical manufacturers develop investment theses, identify opportunities, and evaluate acquisition targets. We know how to assess compatibility from the strategic, cultural, and economic and clinical value perspectives. Clients also seek our guidance in assessing internal teams’ evaluation criteria and decision-making processes, enhancing the results of future efforts.
Once the deal goes through, effective integration is key. We help merging entities establish metrics for monitoring progress, engage stakeholders, define strategic agendas going forward, and redefine accountabilities, roles, responsibilities, and incentives.